Navigation Links
Romark and Chugai Pharmaceutical Enter Into Exclusive Licensing Agreement for Nitazoxanide in Japan
Date:2/17/2009

Chugai Pharmaceutical Gains Rights to Develop and Market Nitazoxanide for the Treatment of Chronic Hepatitis C

TAMPA, Fla., Feb. 17 /PRNewswire/ -- Romark Laboratories, a privately held biopharmaceutical company, and Chugai Pharmaceutical Co. Ltd., a member of the Roche Group, today announced that the two companies have entered into an exclusive license agreement for the development and commercialization of nitazoxanide as a treatment of chronic hepatitis C in Japan.

Under the terms of the agreement, Chugai has paid an upfront payment to Romark, and will make additional payments based on the achievement of certain clinical and regulatory milestones. Romark will participate in profits from product sales in Japan through a supply agreement and royalties.

"Chugai is an excellent partner for us in Japan. They bring substantial expertise in the development and marketing of treatments for chronic hepatitis C exemplified by their experience with Pegasys(R) and Copegus(R)," said Jean-Francois Rossignol, M.D., Ph.D., Chairman and Chief Science Officer of Romark Laboratories, and inventor of the thiazolides. "This agreement is an important step in accelerating the worldwide development and commercialization of nitazoxanide for treating this disease."

Tatsuro Kosaka, Senior Vice President, Head of Lifecycle Management & Marketing Unit of Chugai Pharmaceutical said, "We believe nitazoxanide will be an important addition to current and future treatment regimens for chronic hepatitis C. This agreement demonstrates our commitment to providing innovative new treatments for chronic hepatitis C in Japan."

About Nitazoxanide and Hepatitis C

Nitazoxanide, the first of a new class of broad spectrum antiviral drugs known as the thiazolides, is undergoing worldwide development as a treatment of chronic hepatitis C. Nitazoxanide is a potent inhibitor of hepatitis C virus (HC
'/>"/>

SOURCE Romark Laboratories
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
2. Romark Laboratories Names Emmet B. Keeffe, M.D. Vice President and Chief Medical Officer
3. Romark Laboratories Announces Presentation of New Nitazoxanide Data at 59th Annual AASLD Meeting and 50th Anniversary IASL Meeting in San Francisco
4. Romark Announces Presentation of New Data for Nitazoxanide in Chronic Hepatitis C at AASLD 2008
5. Romark Announces Presentation of New Data for Controlled Release Nitazoxanide in Chronic Hepatitis C
6. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
7. Skystar Bio-Pharmaceutical Announces Second Quarter 2007 Results
8. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
9. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
10. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
11. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/22/2015)... , Nueva Jersey , 22 de enero ... for Biomedical Research abre hoy su llamada a nominaciones ... cuya investigación científica ha hecho, o tiene el potencial ... salud humana. Las nominaciones se aceptarán hasta el 15 ...
(Date:1/22/2015)... , Jan. 22. 2015  Varian Medical Systems (NYSE: ... has been honored for its commitment to sustainability with inclusion ... Varian is the highest ranked healthcare equipment company among the ... during the World Economic Forum at Davos, Switzerland ...
(Date:1/22/2015)... 2015  Derma Sciences, Inc. (Nasdaq: DSCI ... wound care, announces that AMNIOEXCEL® and AMNIOMATRIX®, amniotic ... to the Premier, Inc. Regenerative Skin Grafting contract ... AMNIOEXCEL® and AMNIOMATRIX® product lines, which continue to ...
(Date:12/24/2014)... 24, 2014  United Therapeutics Corporation (NASDAQ: UTHR ... MDT ) has submitted a pre-market approval application to ... use of Medtronic,s SynchroMed ® II implantable drug ... with United Therapeutics, Remodulin ® (treprostinil) Injection delivered ...
Breaking Biology Technology:El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 2El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 3El Dr. Paul Janssen Award for Biomedical Research emite su llamada a los nominados para 2015 4Varian Honored Among World's 100 Most Sustainable Corporations 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 2Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 3Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 4Derma Sciences Expands Access of its AMNIOTIC TISSUE Product Line with New Premier, Inc. Agreement 5United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 2United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 3United Therapeutics Announces Submission Of Pre-Market Approval Application For Implantable Drug Infusion System To Deliver Remodulin 4
... Sinovac Biotech Ltd. (Amex:,SVA), a leading provider of ... Health has purchased approximately RMB 20 million (US$2.86,million) ... to,vaccinate people living in the disaster zone following ... the Healive vaccine to,Sichuan, Shanxi and Gansu provinces., ...
... (NYSE: SGP ) today announced that ... investor relations, effective immediately., In this ... implementing,and continually improving a comprehensive global investor ... formulation and execution of,external and internal investor ...
... American Stock Exchange(R),(Amex(R)) today listed the common ... symbol RNN., Rexahn Pharmaceuticals is a ... discover, develop and commercialize,innovative treatments for cancer, ... unmet medical needs. Rexahn,s compounds are designed,to ...
Cached Biology Technology:Sinovac Receives RMB 20 Million Purchase Order for Healive from China's Ministry of Health to Vaccinate Earthquake Victims 2Schering-Plough Appoints Janet M. Barth Vice President, Investor Relations 2American Stock Exchange Lists the Common Stock of Rexahn Pharmaceuticals, Inc. 2
(Date:1/22/2015)... 2015  Today, FreeWavz ( www.FreeWavz.com ), the developer ... on Fundable, https://www.fundable.com/freewavz . FreeWavz will be ... to meet customer demand. Logo - ... Invented by Dr. ...
(Date:1/22/2015)... Conn. , Jan. 20, 2015 NXT-ID, Inc. (NASDAQ: ... mobile commerce market, reports on the recent success of the Wocket™ smart ... Wocket smart wallet was named as one of the "11 ... the "5 Best Products Launched At CES So Far" by Newseveryday.com and ...
(Date:1/22/2015)... and Markets ( http://www.researchandmarkets.com/research/wxdglm/global_wearable ) has ... Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, ... report to their offering. , ... be worn on the user,s body and have ...
Breaking Biology News(10 mins):FreeWavz Launches on Fundable to Drive Speed-to-Market in 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 2CES Response for NXT-ID's Wocket Smart Wallet Kicks Off 2015 3Global Wearable Technologies Market and Applications, Opportunities, Industry Analysis, Segmentation, Size, Growth, Share, Overview, Trends and Forecast 2014-2020 2
... gets older, people live longer. The price we pay: ... all organs, the immune system does not function flawlessly ... non-university research institutes and two companies is investigating why ... old. The project "GERONTOSHIELD", funded by the German Federal ...
... Researchers with the International Agency for Research on Cancer ... significantly more likely to have several high-risk forms of ... not have lung cancer. These results, which were presented ... 2-6, indicate that HPV antibodies are substantially increased in ...
... particles only billionths of a meter in diameterabout two thousand would ... in a small package to the many millions of people who ... and cell phones, say scientists at Brigham and Women,s Hospital (BWH). ... the team will report a new approach to preventing the ...
Cached Biology News:A better understanding of the aging immune system 2Lung cancer risk rises in the presence of HPV antibodies 2Nanoparticles offer hope for common skin allergy 2Nanoparticles offer hope for common skin allergy 3
... Select Tissue Arrays are intended for laboratory ... were fixed in neutral buffered formalin and ... diagnosis was performed by certified pathologists. ... blocks and relocated into a new recipient ...
The Odyssey Infrared Imaging System is a complete family of products that includes the Odyssey Imager, IRDye labeling reagents and Odyssey software for scan control and data analysis....
... CAST Equine EIA Principle: ... LTC4, LTD4 and LTE4 are ... by 5-lipoxygenase and glutathione-S-transferase. In ... termed "Slow Reacting Substances of ...
... Compound(s) tested through 63 ... assays spanning a broad ... panel includes many non ... several non-selective assays. ...
Biology Products: